China Data

China’s pipeline, in every landscape you run

Sleuth tracks over 22,000 Chinese programs, collected from China’s registries, regulators, stock exchanges, and social feeds, then translated and matched to the same drug and company records as Western programs.

China can’t be a blind spot

Chinese programs show up in every biopharma team’s work: as the competitor in your landscape, the asset you might license, and the next wave of clinical data. Leave China out, and you’re missing half of the field.

Business Development

84

companies licensed Chinese assets in 2025, up from 17 in 2021.

Competitive Intelligence

~50%

of the world’s ADCs, bispecifics, and CAR-T programs come from Chinese companies.

Clinical Strategy

~2,500

Chinese assets are in late-stage development now, so a wave of clinical data is on its way.

Investing

375+

out-licensing deals from Chinese companies since 2021.

Sleuth analysis of China-originated programs and out-licensing deals, 2026.

Find Chinese assets earlier

China accepts more than 2,000 innovative IND applications a year, and those programs are disclosed first in Chinese: in patent filings, WeChat posts, Chinese medical meetings, and IND acceptances. Sleuth reads all of them, so you see a program when it’s disclosed, not months later when a database catches up.

A Chinese version for every Western source

Sleuth reads 13 Chinese sources and China’s major medical meetings in the original Chinese, from the drug regulator’s trial registry to biotechs’ WeChat accounts.

Trial registries

China Drug Trial Registration Platform (CDE), ChiCTR, ITMCTR

Every drug trial China approves, often listed earlier and in more detail than on ChiCTR.

Regulators

NMPA, CDE

Approvals, IND acceptances, and the breakthrough, priority, and conditional approval lists.

Stock exchanges

HKEXnews, CNInfo

Prospectuses and announcements from Hong Kong’s 18A biotechs and Shanghai’s STAR Market.

Patents

China National Intellectual Property Administration

Where Chinese biotechs usually file first on a new program.

Research

Chinese-language journals, theses, and conference papers

Clinical and pharmacology work that’s largely missing from PubMed.

Medical meetings

CSCO, CACA, the Chinese Society of Hematology, the Chinese Diabetes Society, the China Heart Congress, and more

Data presented in China, often before it’s published.

Company news

WeChat official accounts

Pipeline, financing, and trial updates, sometimes before any English release.

Patients and pricing

China CDC, China National Cancer Center, National Reimbursement Drug List (NHSA)

Patient numbers, and what China’s national insurance pays for.

Chinese broker research

Chinese banks and brokers, by kind

Analyst notes on Chinese companies and their programs, translated.

See every source on the Data overview

Chinese data you can trust

Chinese programs are spread across registries, exchange filings, and company posts, in Chinese and English. Sleuth translates every source, matches it to one record, and checks it against the others, so you can see where every value came from and how sure to be of it.

1

Translated

Every Chinese source is translated into English, and the original is one click away.

2

Matched

Chinese companies keep their Chinese and English names on one record, and a drug’s Chinese code, its INN, and its partner’s name all lead to the same program.

3

Checked

Every value shows its source and a confidence score. Sleuth checks Chinese records against Western ones, so you can see where they agree and where they don’t.

See how Sleuth checks every value

Ask Claude about China, with China’s own sources behind it

Connect Sleuth to Claude, ChatGPT, Copilot, or other AI tools, and it answers from the same knowledge base as Studio, with China’s registries, filings, and medical meetings already translated and matched. Chinese and Western programs come back in one answer, each with its source.

Claude on its own

Claude searches the open web the day you ask. It finds the Chinese programs that made English news, but it can’t reach China’s trial registries, exchange filings, or WeChat posts.

Claude with Sleuth connected

Claude works from the same knowledge base as Studio, with China’s registries, filings, patents, and WeChat posts already translated and matched to the drugs and companies you know.

With Sleuth connected, AI tools found 63% more of the landscape in Sleuth’s benchmark.

Set up Sleuth in Claude, ChatGPT, or CopilotSet up in Claude, ChatGPT, or Copilot
The Wall Street Journal

The China data behind the Wall Street Journal’s fast-follower story

The Wall Street Journal used Sleuth’s analysis of Chinese regulatory filings, press releases, and trial registries to show how quickly Chinese biotechs follow a Western breakthrough, and how many of those programs Western pharma licenses back.

Check it on a program you know

Ask about a target, a modality, or a competitor you already track, and see which Chinese programs Sleuth finds and where each one came from.

Competitive Intelligence

“Which Chinese companies have a [target] program, how far along is each, and has any been licensed outside China?”

Business Development

“Which China-origin bispecifics in Phase 2 or later have no partner outside China yet?”

Clinical Strategy

“Which Chinese programs started trials after [competitor]’s last readout in [indication]?”

See what China has in your field

Set up in Claude, ChatGPT, or Copilot